Lead discovery action

In 1985, it was reported by Hsiang et al. [43] that the cytotoxic activity of 20-(S)-camptothecin (CPT III) was attributed to a novel mechanism of action involving the nuclear enzyme topo I, and this discovery of unique mechanism of action revived the interest in CPT and its analogues as anticancer agents. CPT stabilizes the covalent, reversible topo I-DNA complex leading to the inhibition of DNA synthesis in mammalian cells and interferes with the topo I breakage-reunion reaction [44]. Clinical trials and structure-activity relationships have demonstrated the requirement of the a-hydroxy group, the... 

The development of new chemotherapeutic agents for a particular disease state continues to depend to a significant degree on the discovery of a lead compound , which can be further developed into a viable drug candidate. A very important aspect of this process is to find novel substances that will provide a new mode of action for the treatment of a specific disease. From a historical standpoint, the isolation of novel substances from natural sources has often provided this lead compound. The number of new drugs and their origin for the period 1981-2002 has recently been summarized [1], and, of 79... 

Although its mode is uncertain, sodium nitroprusside (SNP) is one of the most valuable vasodilators. Its use in clinical practice is suspect as the cyano-ligands render cyanide poisoning a possibility. However for ex vivo experiments this consideration is less important but the possibility of some biological action due to these ions remains. The mechanism by which SNP acts as a vasodilator is not fully understood. With the discovery of a physiological role for NO there has been renewed interest in mechanistic studies of reactions involving SNP and a re-examination of studies of SNP undertaken before 1987. So far, only one simple reaction leading to the release... 

Drug metabolism has been recognized as one of the key factors in the discovery of new chemical entities. A lead compound needs to not only interact with the target enzyme/receptor but also remain over a certain threshold concentration at the site of action for a defined period to produce the desired therapeutic effect. Drug metabolism together with absorption, distribution and excretion are among the factors that influence the final time-concentration relationship of drugs and therefore the potential efficacy of the compound [1],... 

This approach offers two opportunities to discover clinically relevant compounds. The first is the compounds identified directly in the Cytection screens. Second, appreciating that these compounds have the desirable biological endpoints, they can be used as "molecular probes" to determine their putative mechanism(s) of action. This "reverse drug discovery"9 identifies "validated" targets that can be the basis for mechanistic screens that could lead to the discovery of additional compounds. 

The use of plants for medicinal purposes is an ancient practice. Nature, with its wealth of traditional knowledge has been the source of inspiration for numerous drugs currently used for the improvement of life as well as treatment for a cure. Considering the beneficial role of many plants and fruits, they were included in the human diets. In many instances, the knowledge of the underlying mechanism of action of a particular natural product is incomplete. Continuous investigation can lead to new mechanisms and new structures, which may open up entirely new windows and perspectives. For instance, before the discovery of apicidin and bispyri-dinium diene, it was believed that unless there is a classical chelator for zinc ion, it cannot be a HDAC inhibitor. SAHA has been approved by FDA, which is inspired from the natural product trichostatin. The natural product, romidepsin has also been approved by FDA and many are on clinical trials. Currently, isozyme-selective inhibition for HDAC is at its nascent stage. The invention of some novel molecules or invention of some novel natural product structures with synthetic modifications will solve the problem. 

---